preprint
<title>Abstract</title> Purpose A dosing strategy for ritonavir-boosted atazanavir (ATV/r) to overcome the drug-drug interaction (DDI) effect with standard doses of rifampicin (10mg/ kg) was investigated in children aged between 7 and 18 years who were divided into 3 weight bands: 25-30 kg, 30-49 kg, and 50-70 kg. Methods We developed a paediatric physiologically-based pharmacokinetic (PBPK) model from a validated adult PBPK model with the necessary DDI components. The paediatric PBPK model was validated using relevant clinical data of ATV/r alone and rifampicin alone in children. Results Dose escalation to twice-daily dosing of ATV/r was predicted to boost ATV C<sub>trough</sub> adequately. With ATV/r 300/100 mg twice daily dosing in the presence of standard doses of rifampicin, predicted ATV C<sub>trough</sub> was higher than 150 ng/ml in over 90% of the paediatric population. Conclusions This model results suggests ATV/r 300/100 mg twice daily could maintain sufficient concentrations for antiviral efficacy when co-administered with standard dose of rifampicin taken once daily in children between 7 and 18 years. However, clinical studies are still warranted to confirm safety and efficacy of the dose escalation in children.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21203/rs.3.rs-5068722/v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
